Search results
Results from the WOW.Com Content Network
AbbVie (NYSE: ABBV) has long been a darling of dividend growth investors, and for good reason. Since its spinoff from Abbott Laboratories in 2013, the pharmaceutical titan has been a dividend ...
And since it split from Abbott in 2013, AbbVie has increased its dividend by 310%. The stock's forward yield is now around 3.8%, compared to the S&P 500 's average of 1.3%.
Abbvie , the Abbott spinoff that made its New York Stock Exchange debut at the start of the year, recently announced that its chief scientific officer will retire in the coming months. A new CSO ...
This spin-off company, named AbbVie, was formed on April 10, 2012. [8] The separation was fully effective January 1, 2013, and AbbVie was officially listed on the New York Stock Exchange (ABBV) on January 2, 2013. [9] [10]
Nearly every investor remotely interested in health care stocks kept a watch on the recent spinoff of AbbVie by Abbott . As well they should: It involved the creation of a new business with sales ...
For some Abbott Labs shareholders, the new year brought with it a new company called AbbVie. Formerly Abbott's branded pharmaceuticals business, shares of the new stock were distributed to ...
Hospira was an American global pharmaceutical and medical device company with headquarters in Lake Forest, Illinois.It had approximately 19,000 employees. [1] Before its acquisition by Pfizer, Hospira was the world's largest producer of generic injectable pharmaceuticals, [2] manufacturing generic acute-care and oncology injectables, as well as integrated infusion therapy and medication ...
With the impending spinoff of its branded-drug business, Abbott Labs (NYS: ABT) is losing a massive blockbuster drug in Humira. It's a confusing event to understand, with many investors left ...